Citizens Jmp Has Lowered Expectations for Stryker (NYSE:SYK) Stock Price

Key Points

• Citizens JMP lowered Stryker’s price target to $390 from $400 while maintaining a “market outperform” rating, implying approximately 25% upside from the stock’s reported $311.12 price.
• Stryker’s third-quarter results missed expectations: EPS was $3.52 versus $3.55 expected, and revenue was $6.52 billion versus $6.62 billion. The company also reduced its 2026 organic sales-growth and adjusted EPS guidance.
• Despite a “Moderate Buy” consensus rating and a $362.36 average analyst target, concerns include slower growth, operational constraints, and significant insider selling totaling about $118.2 million over the past 90 days.

Stryker (NYSE:SYK - Get Free Report) had its price target reduced by stock analysts at Citizens Jmp from $400.00 to $390.00 in a report released on Friday, Benzinga reports. The brokerage currently has a "market outperform" rating on the medical technology company's stock. Citizens Jmp's price target suggests a potential upside of 25.36% from the stock's current price.

Other equities analysts have also recently issued research reports about the stock. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. Raymond James Financial restated an "outperform" rating on shares of Stryker in a research note on Friday. BMO Capital Markets reaffirmed an "outperform" rating and issued a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. dropped their target price on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $362.36.

Stryker Trading Up 2.3%

NYSE SYK opened at $311.12 on Friday. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $119.34 billion, a price-to-earnings ratio of 32.24, a price-to-earnings-growth ratio of 1.96 and a beta of 0.78. The firm's fifty day moving average price is $293.56 and its 200 day moving average price is $324.86.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company had revenue of $6.52 billion for the quarter, compared to analysts' expectations of $6.62 billion. During the same period in the prior year, the business earned $3.19 EPS. The business's quarterly revenue was up 7.6% compared to the same quarter last year. On average, sell-side analysts expect that Stryker will post 14.93 earnings per share for the current fiscal year.

Insider Activity

In other Stryker news, insider Dylan Crotty sold 441 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company's stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock worth $118,197,701 in the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stryker

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE bought a new stake in Stryker during the second quarter worth about $1,404,284,000. Legal & General Group Plc acquired a new position in shares of Stryker in the 2nd quarter valued at about $707,212,000. Jupiter Topco LLC acquired a new stake in Stryker in the second quarter worth $681,581,000. Corient Private Wealth LP acquired a new stake in Stryker in the second quarter valued at approximately $323,035,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker during the second quarter worth about $464,506,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6%–7.7% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19 a year earlier. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management is navigating manufacturing constraints in the vascular business and lingering operational effects from the cybersecurity incident disclosed in March. A new CEO is also taking over as the company reassesses its growth trajectory, making the 2027 starting point a key investor focus. Stryker’s Guidance Cut Rattles Investors
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 missed the roughly $3.55–$3.56 analyst consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The earnings and sales misses triggered a significant selloff. Stryker Q3 2026 earnings revenue and EPS miss
• Negative Sentiment: Stryker lowered its 2026 organic net sales growth forecast to 6.5%–7.0% from 8.3%–9.3%, while adjusted EPS guidance moved to $14.80–$14.90 from $14.95–$15.10. The larger sales reduction suggests demand, supply, or execution concerns beyond a one-quarter earnings miss. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Analysts subsequently cut their forecasts and price targets, reinforcing concerns about slower growth, margin pressure, and the company’s ability to regain momentum in 2027. Stryker Analysts Cut Their Forecasts

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.